Form 4: UTHR CEO Rothblatt Executes Pre-Arranged Stock Sales

United Therapeutics Chairperson & CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 11,990 shares in late September 2025 under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the company's common stock.
• The transactions occurred on September 29, 2025, and September 30, 2025.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• On September 29, 2025, 4,000 stock options were exercised at a price of $120.26 per share.
• On September 29, 2025, a total of 4,000 shares were sold in multiple trades at weighted average prices ranging from $416.3797 to $430.8125.
• On September 30, 2025, another 4,000 stock options were exercised at a price of $120.26 per share.
• On September 30, 2025, 4,000 shares were sold at a weighted average price of $422.8394.
• Following these transactions, Rothblatt directly holds 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse, 324,518 shares by a family trust, 258,117 shares by another family trust, 45,596 shares by a third family trust, and 15,962 shares by a fourth family trust.
• A total of 226,000 stock options with an exercise price of $120.26 and an expiration date of March 15, 2026, remain beneficially owned.

Sentiment

Score: 6

Explanation: While insider selling can be viewed negatively, the transactions were conducted under a pre-arranged 10b5-1 plan, which signals transparency and reduces concerns about opportunistic selling. The significant profit realized from option exercises is a positive for the executive.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider stock sales, which reduces concerns about opportunistic selling.
• The exercise of stock options at $120.26 and subsequent sales at significantly higher prices (e.g., up to $430.8125) demonstrate the profitability of the options for the insider.

Negatives

• Significant insider selling by a key executive (Chairperson & CEO) could be perceived negatively by some investors, even if pre-arranged.
• The reduction in direct beneficial ownership to 130 shares, while indirect holdings remain substantial, represents a decrease in direct exposure to the company's stock performance for the reporting person.

Risks

• Market volatility could impact the actual sale prices achieved for future transactions under the 10b5-1 plan.
• The expiration of a tranche of 294,000 stock options on March 15, 2026, creates a deadline for their exercise, potentially leading to further sales.

Future Outlook

The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025. This indicates further planned transactions are expected.

Management Comments

• "This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025."
• "This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025."

Industry Context

This filing reflects routine insider stock transactions, common across publicly traded companies, particularly for executives managing long-term equity compensation. The use of a Rule 10b5-1 plan is a standard practice to mitigate concerns about insider trading by pre-scheduling sales.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance and transparency in managing insider stock transactions, similar to plans adopted by executives at companies like Apple (AAPL) or Microsoft (MSFT) to systematically liquidate vested equity awards.
• The exercise of options and subsequent sale is a common method for executives to realize value from their compensation, comparable to how executives at pharmaceutical peers manage their equity.

Stakeholder Impact

• Shareholders: May view the insider selling with caution, but the 10b5-1 plan mitigates concerns. The transactions reflect the executive realizing value from their compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continuation of transactions under the existing 10b5-1 trading plan until its termination, which is expected by December 31, 2025, or upon exhaustion of the specified stock options.

Key Dates

Recommendation

This Form 4 filing primarily details routine, pre-scheduled insider stock option exercises and sales. While significant insider selling can sometimes signal a lack of confidence, the execution under a Rule 10b5-1 plan mitigates this concern, indicating a planned liquidity event rather than a reaction to new, negative information. The filing does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, pending further operational or financial updates.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Form 4, insider trading, stock options, 10b5-1 plan, beneficial ownership, CEO, stock sale